在患有慢性阻塞性肺病的患者急性恶化期间,血中乙氨基酸的稳定性
Qidong Chen1, Wei Ji1, Hongyu Wang1
1Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Street, Fengze District, Quanzhou, Fujian, China.
BMC pulmonary medicine
|December 19, 2025
概括
在COPD急性恶化 (AECOPD) 期间,血中乙氨基酸细胞数量发生显著波动,这质疑它们作为稳定的生物标志物的可靠性. 对于吸入性皮质类固醇 (ICS) 治疗决定,建议进行动态解释和趋势评估.
科学领域:
- 肺部医学 肺部医学
- 临床生物标志物 临床生物标志物
- 呼吸系统疾病研究 呼吸系统疾病研究
背景情况:
- 黄金指导方针建议血液中乙酸氨基基细胞作为COPD吸入性皮质类固醇 (ICS) 治疗的生物标志物.
- 然而,COPD急性恶化 (AECOPD) 期间血液中乙氨基酸细胞计数的稳定性和可靠性仍然不确定.
研究的目的:
- 在AECOPD期间评估血中乙氨基酸细胞计数的稳定性和患者内变异性.
- 评估已确立的乙氨基基值在恶化期间指导ICS治疗的稳定性.
主要方法:
- 对3311名住院AECOPD患者的血中乙氨基酸细胞数据 (2018-2023) 的回顾性分析.
- 使用线性混合效应模型评估乙酸细胞分布,纵向趋势和患者内部变异性.
- 评估跨越值和重新分类率,包括模拟类固醇减少场景.
主要成果:
- 在AECOPD住院治疗期间,血液中乙氨基酸细胞表现出显著的患者内部变异性 (CV%中位数为76.6%).
- 经常发生跨越值 (≥100细胞/μL:45.7%;≥300细胞/μL:22.7%) 和重新分类.
- 模拟的类固醇降低只显示了小小的低细胞数量下降,在关键值的~13%波动.
结论:
- 在AECOPD期间,血中乙氨基酸细胞计数显示出相当大的动态变化.
- 对于关于ICS治疗的临床决策,建议使用动态解释和趋势评估,而不是单个测量.
- 在急性恶化期间,重新检测或监测乙酸细胞趋势对于准确指导至关重要.
更多相关视频
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
01:22Chronic Obstructive Pulmonary Disease
2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K
01:26COPD: Management Using Bronchodilators and Corticosteroids
700
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
700
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.1K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:26Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K